Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Gracell Reports Positive Results for FasT CAR-19 in Leukemia Patients

publication date: Jun 21, 2019

Gracell Biotechnologies, a Suzhou immunotherapy company, announced positive preliminary results from a trial of its FasT CAR-19 investigational cell gene therapy. Gracell's FasT CAR product reduces preparation time to 24 hours, compared to an average of two weeks in other genetically modified T-cells candidates. In a group of 16 adolescent and adult patients with B-cell acute lymphoblastic leukemia (B-ALL), all 16 achieved complete remission (with or without complete blood count recovery). Each of the patients had been previously treated with multiple therapies. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China